Crossmark

Telomere length predicts for outcome to FCR chemotherapy in CLL

Crossref DOI link: https://doi.org/10.1038/s41375-019-0389-9

Published Online: 2019-01-30

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Norris, Kevin

Hillmen, Peter

Rawstron, Andrew http://orcid.org/0000-0003-0798-9790
Hills, Robert

Baird, Duncan M. http://orcid.org/0000-0001-8408-5467
Fegan, Christopher D.

Pepper, Chris
Funding

Funding for this research was provided by:

Wales Cancer Research Centre

Bloodwise
License Information

Text and Data Mining valid from 2019-01-30
More Information

Article History

Received: 19 October 2018

Revised: 13 December 2018

Accepted: 28 December 2018

First Online: 30 January 2019

Compliance with ethical standards

:

: KN, CP, DMB, and CDF are all co-inventors of patents relevant to the content of this manuscript and hold shares in a University spin-out company set up to provide telomere length testing. PH, AR, and RH declare that they have no conflict of interest.